CN105263963B - 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法 - Google Patents

伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法 Download PDF

Info

Publication number
CN105263963B
CN105263963B CN201480031344.7A CN201480031344A CN105263963B CN 105263963 B CN105263963 B CN 105263963B CN 201480031344 A CN201480031344 A CN 201480031344A CN 105263963 B CN105263963 B CN 105263963B
Authority
CN
China
Prior art keywords
pcsk9
patients
antibody
pcsk9 inhibitor
visit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480031344.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN105263963A (zh
Inventor
G·斯维尔戈尔德
S·梅利斯
W·J·萨赛拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority to CN202110182897.4A priority Critical patent/CN113144195A/zh
Publication of CN105263963A publication Critical patent/CN105263963A/zh
Application granted granted Critical
Publication of CN105263963B publication Critical patent/CN105263963B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
CN201480031344.7A 2013-05-30 2014-05-29 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法 Active CN105263963B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110182897.4A CN113144195A (zh) 2013-05-30 2014-05-29 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361828730P 2013-05-30 2013-05-30
US61/828,730 2013-05-30
US201361889553P 2013-10-11 2013-10-11
US61/889,553 2013-10-11
US201361901212P 2013-11-07 2013-11-07
US61/901,212 2013-11-07
PCT/US2014/040050 WO2014194111A1 (en) 2013-05-30 2014-05-29 Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110182897.4A Division CN113144195A (zh) 2013-05-30 2014-05-29 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法

Publications (2)

Publication Number Publication Date
CN105263963A CN105263963A (zh) 2016-01-20
CN105263963B true CN105263963B (zh) 2021-03-05

Family

ID=51205567

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110182897.4A Pending CN113144195A (zh) 2013-05-30 2014-05-29 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法
CN201480031344.7A Active CN105263963B (zh) 2013-05-30 2014-05-29 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110182897.4A Pending CN113144195A (zh) 2013-05-30 2014-05-29 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法

Country Status (12)

Country Link
US (2) US20140356370A1 (enExample)
EP (1) EP3004172B1 (enExample)
JP (1) JP6423868B2 (enExample)
KR (1) KR20160013046A (enExample)
CN (2) CN113144195A (enExample)
AU (1) AU2014274077B2 (enExample)
CA (1) CA2912101A1 (enExample)
EA (1) EA201592304A1 (enExample)
IL (1) IL242251B (enExample)
TW (1) TWI682780B (enExample)
WO (1) WO2014194111A1 (enExample)
ZA (1) ZA201507798B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
MX366458B (es) 2011-01-28 2019-07-10 Sanofi Biotechnology Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9.
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
MX363642B (es) 2011-09-16 2019-03-28 Regeneron Pharma Metodos para reducir los niveles de lipoproteina (a) administrando un inhibidor de proproteina convertasa subtilisina kexina-9 (pcsk9).
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
CN105705521A (zh) 2013-06-07 2016-06-22 再生元制药公司 通过施用pcsk9抑制剂抑制动脉粥样硬化的方法
ES2914978T3 (es) * 2013-10-11 2022-06-20 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
MX2016006226A (es) 2013-11-12 2016-09-07 Sanofi Biotechnology Regimenes de dosificacion para uso con inhibidores de pcsk9.
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
RU2735521C2 (ru) 2014-07-16 2020-11-03 Санофи Байотекнолоджи Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
WO2016100615A2 (en) * 2014-12-18 2016-06-23 The University Of Chicago Methods and composition for neutralization of influenza
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
IL264631B2 (en) 2016-08-16 2024-05-01 Regeneron Pharma A method for quantifying individual antibodies from a mixture
EP4071469B1 (en) 2016-10-25 2025-04-09 Regeneron Pharmaceuticals, Inc. Methods for chromatography data analysis
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US11325945B2 (en) 2017-04-12 2022-05-10 Cadila Healthcare Limited Peptide based PCSK9 vaccine
US20200223941A1 (en) * 2017-06-30 2020-07-16 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition comprising pcsk-9 antibody and use thereof
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
CN111465848B (zh) 2017-12-13 2023-11-28 里珍纳龙药品有限公司 管理层析柱床支架的装置和系统及相关方法
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
IL323016A (en) * 2019-11-18 2025-10-01 Ad Pharmaceuticals Co Ltd Anti-pcsk9 antibody and its use
US20230272112A1 (en) 2019-12-10 2023-08-31 Regeneron Pharmaceuticals, Inc. Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
IL300439A (en) 2020-08-25 2023-04-01 Regeneron Pharma Treatment of sepsis with PCSK9 and LDLR modulators
CN116189765B (zh) * 2023-02-23 2023-08-15 上海捷易生物科技有限公司 一种iPS细胞遗传学风险评估系统及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077854A1 (en) * 2008-12-15 2010-07-08 Regeneron Pharamaceuticals, Inc. High affinity human antibodies to pcsk9
WO2012146776A1 (en) * 2011-04-29 2012-11-01 Sanofi Test systems and methods for identifying and characterising lipid lowering drugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1471152A1 (en) * 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
MX363642B (es) * 2011-09-16 2019-03-28 Regeneron Pharma Metodos para reducir los niveles de lipoproteina (a) administrando un inhibidor de proproteina convertasa subtilisina kexina-9 (pcsk9).

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077854A1 (en) * 2008-12-15 2010-07-08 Regeneron Pharamaceuticals, Inc. High affinity human antibodies to pcsk9
WO2012146776A1 (en) * 2011-04-29 2012-11-01 Sanofi Test systems and methods for identifying and characterising lipid lowering drugs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PCSK9 inhibition and LDL cholesterol lowering: The biology of an attractive therapeutic target and critical review of the latest clinical trials;Rhainds D等;《Clinical Lipidology》;20121201;第7卷(第6期);第621-640页 *
PCSK9在高胆固醇血症中的作用研究进展;崔琴等;《医学综述》;20100831;第16卷(第16期);第2454-2456页 *
Rhainds D等.PCSK9 inhibition and LDL cholesterol lowering: The biology of an attractive therapeutic target and critical review of the latest clinical trials.《Clinical Lipidology》.2012,第7卷(第6期),第621-640页. *

Also Published As

Publication number Publication date
HK1216896A1 (en) 2016-12-09
EP3004172B1 (en) 2019-11-27
TWI682780B (zh) 2020-01-21
JP2016522211A (ja) 2016-07-28
CN113144195A (zh) 2021-07-23
IL242251B (en) 2020-02-27
CN105263963A (zh) 2016-01-20
CA2912101A1 (en) 2014-12-04
KR20160013046A (ko) 2016-02-03
TW201536315A (zh) 2015-10-01
WO2014194111A1 (en) 2014-12-04
US20140356370A1 (en) 2014-12-04
ZA201507798B (en) 2017-04-26
AU2014274077B2 (en) 2019-09-26
EP3004172A1 (en) 2016-04-13
JP6423868B2 (ja) 2018-11-14
AU2014274077A1 (en) 2015-11-19
EA201592304A1 (ru) 2016-04-29
US20190330371A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
CN105263963B (zh) 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法
JP7467538B2 (ja) ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法
EP2756004B1 (en) INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS
US11904017B2 (en) Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
KR102482375B1 (ko) 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법
JP2019512472A (ja) Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
JP7104108B2 (ja) ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法
HK1216896B (en) Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations
EA041556B1 (ru) Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией подвергающихся аферезу липопротеинов
HK1255470B (en) Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
HK1236136B (en) Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
HK1236136A1 (en) Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant